https://twitter.com/arvindcanchi/status/1726799837797208490Posters at #KidneyWk Tirzepatide demonstrated an increase in CysC-eGFR and reductions in UACR compared with placebo, suggesting renoprotective effects. These results warrant a long-term, prospective kidney outcome trial for people with obesity or overweight. SURMOUNT-1 Trial 👉… https://bit.ly/3QNIoH1 https://bit.ly/3R7pJar
— Arvind Canchi (Conjeevaram)🇮🇳 (@arvindcanchi) Nov 21, 2023
Monday, November 20, 2023
@arvindcanchi
http://twitter.com/arvindcanchi
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment